Sai Life Sciences announced a strategic collaboration with Mabtech on 28 January 2026 to advance immunology research. The pact establishes Sai’s Boston laboratory as a co-marketed US hub for Mabtech’s EYRA platform, as disclosed under SEBI Regulation 30.
Source: Sai Life Sciences Limited Press Release (NSE Exchange Filings) | Published on Jan 28, 2026
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Sai Life Sciences Limited (NSE Exchange Filings), the company informed stock exchanges about a new collaboration with Mabtech. The disclosure was made on 28 January 2026. It was submitted under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The announcement was filed with both the National Stock Exchange of India and the Bombay Stock Exchange. The filing was shared for information and record purposes.
The collaboration involves Sai Life Sciences and Mabtech working together on immunology research services.
Also Read: Akzo Nobel India Board Approves Proposal to Change Company Name
Sai Life Sciences announced a collaboration with Mabtech
Disclosure made on 28 January 2026 under SEBI Regulation 30
Boston site to act as US execution hub
EYRA platform to be used for immunology services
Sai Life Sciences share price stood at ₹851.00 at 16:00 IST
Under the collaboration, Sai Life Sciences’ Boston laboratory will act as a US execution and demonstration hub. The facility will support services linked to Mabtech’s EYRA™ platform.
The EYRA platform has been installed at Sai’s Boston discovery site. The site will be used to carry out immunology assay services under the agreement.
The Boston laboratory will also be used for demonstration activities related to the platform.
Also Read: NTPC Green Energy Begins 130.47 MW Commercial Operations from Khavda Solar
Mabtech and Sai Life Sciences will jointly deliver immunology assay services. These services include multiplex cytokine assays and phenotyping workflows.
The services will support research in immuno-oncology, vaccines, inflammation, and cellular therapy. The collaboration covers work for biopharma and biotech companies in these areas.
No financial details of the agreement were disclosed in the exchange filing.
The EYRA platform allows the detection of multiple immune markers in a single test run. It uses integrated software to support laboratory workflows.
According to the press release, the platform was developed through long-term research efforts. It is designed to support immunology research activities.
The platform will be used at the Boston site for joint service delivery.
Particulars | Details |
Partner Companies | Sai Life Sciences Limited, Mabtech |
Type Of Agreement | Strategic collaboration |
Platform Used | EYRA™ |
Location | Boston, United States |
Research Area | Immunology |
Regulatory Reference | SEBI Regulation 30 |
Disclosure Date | 28 January 2026 |
Sai Life Sciences stated that the announcement complies with SEBI Listing Regulations. The disclosure was signed by the Company Secretary and Compliance Officer.
The company said further details will be shared through the attached press release. No additional commercial information was included.
Sai Life Sciences' share price data from the National Stock Exchange showed the stock trading at ₹851.00 as of 28 January 2026 at 15:30 PM IST.
The share price was higher by ₹30.75, or 3.75%, compared with the previous close. The stock opened at ₹820.30 during the session.
It recorded an intraday high of ₹852.00 and a low of ₹805.10. The previous closing price stood at ₹820.25. The volume-weighted average price was ₹843.07.
The Sai Life Sciences share price data reflects exchange information available at the stated time.
Also Read: TCS Incorporates Moroccan Subsidiary to Expand Nearshore IT Services Globally
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading